What ExploRNA Therapeutics does

ExploRNA Therapeutics is a privately held Polish biotechnology company founded in 2021 as a spin-off from the University of Warsaw, headquartered in Warsaw with a small team of 11–50 employees. The company develops and commercializes next-generation mRNA cap analogs — proprietary chemical reagents that cap the 5' end of messenger RNA to enhance protein expression, stability, translation efficiency, and to reduce dsRNA formation during in vitro transcription. Its commercial portfolio includes ExploCap (a cost-effective Cap 1 alternative) and the AvantCap family (AvantCap AG, Q1, and Q2), with the latter being the first market-available Cap 2 modification, supported by a proprietary library of over 150 cap analogs and patent protection granted in the United States, Japan, and the European Patent Office.

ExploRNA serves pharmaceutical and biotechnology companies, contract manufacturers, and academic researchers developing mRNA vaccines and therapeutics, addressing pain points around protein yield, dose requirements, manufacturing cost, and purification. The company operates a horizontal, B2B-dominant go-to-market: cap analogs and Custom mRNA services are sold direct-to-customer through the explorna.com e-commerce shop with global shipping; proprietary capping technology is also licensed to pharmaceutical partners for use in their own mRNA manufacturing; and the company maintains distribution and co-development alliances, notably with OZ Biosciences (channel/distribution) and Primrose Bio (co-development of polymerases + cap analog stacks).

Revenue mechanics are diversified across one-time cap analog product sales, custom mRNA synthesis services, and technology licensing/royalties, with public unit pricing of €500–€4,800 per 10–100 µmol pack across the SKU range. To date, the company's most material cash inflows are non-dilutive grants rather than commercial sales, including a $813,578 Bill & Melinda Gates Foundation award (2022) and PLN 19.4M from Poland's National Centre for Research and Development (2024) for an anti-cancer mRNA vaccine program, with additional PLN 4.57M from the Agency for Medical Research for an ARDS mRNA therapy project.

Name

ExploRNA Therapeutics

Legal name

ExPLoRNA Therapeutics Spółka z Ograniczoną Odpowiedzialnością

Website

https://explorna.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

ExploRNA Therapeutics is a Polish biotech that develops and sells proprietary next-generation mRNA cap analogs (ExploCap, AvantCap AG/Q1/Q2) and Custom mRNA services to pharmaceutical companies, biotech firms, contract manufacturers, and academic researchers developing mRNA vaccines and therapeutics.

Ownership category

akta.pro rank

Product category

mRNA Cap Analogs

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)

akta.pro secondary industries

Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• MRNA cap analogs
• Biotechnology reagents
• Nucleotide manufacturing
• Co-transcriptional capping
• MRNA therapeutics platform

Headquarters

HQ city

Warsaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Cap analog product sales: Direct sales of proprietary cap analogs (AvantCap AG, AvantCap Q1, AvantCap Q2, ExploCap) to pharmaceutical companies, biotech firms, and academic researchers through the company's e-commerce platform.
2. Custom mRNA synthesis: Custom mRNA preparation services using proprietary cap analogs for research use only, sold through the company's shop.
3. Technology licensing: Licensing of proprietary capping technology to pharmaceutical partners for use in their mRNA manufacturing processes and therapeutic development programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

ExploRNA Therapeutics develops and manufactures proprietary next-generation mRNA cap analogs (ExploCap, AvantCap AG, AvantCap Q1, AvantCap Q2) used by pharmaceutical and biotechnology companies to produce mRNA vaccines and therapeutics. The company sells these physical nucleotide reagents directly via its e-commerce shop and licenses its capping technology to pharma partners, while also offering custom mRNA synthesis services built on its proprietary cap analogs.

Product overview

ExploRNA Therapeutics is a biotechnology company offering a family of proprietary cap analog products for mRNA capping in vaccines and therapeutics. The core product portfolio centers on two lead cap analog brands: ExploCap (a cost-effective Cap 1 alternative) and the AvantCap family (featuring trinucleotide and tetranucleotide variants with enhanced biological properties). AvantCap AG delivers up to 6-fold superior protein expression through N6-benzyl modification, while AvantCap Q1 and Q2 introduce tetranucleotide designs for broader IVT compatibility and Cap 2 modification respectively. The company also offers Custom mRNA products manufactured with these proprietary cap analogs as an add-on service.

Differentiator

Problem solved

Functional benefit

Products and services

• ExploCap
• AvantCap AG Flagship trinucleotide cap analog featuring N6-benzyl modification at the first transcribed nucleotide, offering up to 6-fold increased protein production compared to natural cap1 in vivo, sold to pharmaceutical and biotechnology customers developing mRNA vaccines and therapeutics.
• AvantCap Q1
• AvantCap Q2
• Custom mRNA Synthesis Service

Quantifiable outcome

• Up to six-fold increase in human erythropoietin production compared with natural cap1 in mouse studies
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• OZ BiosciencescoreChannel Partner/ Reseller/ Distributor · 3 February 2026Strategic partnership where OZ Biosciences integrates ExploRNA's proprietary ExploCap technology into its mRNA offering. OZ Biosciences distributes ExploCap-capped mRNA products globally, broadening access to next-generation RNA capping technology.
• Primrose BiocoreStrategic or Co-development Partner · 3 September 2024Strategic partnership to jointly develop and market products for mRNA medicines. Primrose Bio's Prima RNApols RNA polymerases combined with ExploRNA's cap analogs create co-optimized solutions for enhanced mRNA quality, manufacturing performance, and therapeutic safety and efficacy.
• University of WarsawcoreStrategic or Co-development PartnerExploRNA Therapeutics is a spin-off company from the University of Warsaw, founded by researchers from the university. The company maintains ongoing collaborations with university researchers on scientific publications and cap analog development.
• WackerminorImplementation/ SI/ Consulting PartnerContract manufacturer partnership for production of nucleotides and nucleic acids derivatives. ExploRNA maintains active collaborations with contract manufacturers including Germany's Wacker.
• Alliance for mRNA MedicinesminorOthersIndustry organization membership. ExploRNA joined the Alliance for mRNA Medicines, with Director of Biology Dominika Nowis joining AMM's Board of Directors to work on key challenges for the mRNA field.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• TriLink BioTechnologies: TriLink BioTechnologies is the most direct peer, manufacturing CleanCap cap analogs (the current industry standard) and offering custom mRNA synthesis services with GMP options. They compete head-to-head with ExploRNA's ExploCap and AvantCap lines for the same pharmaceutical and biotech customers.
• Jena Bioscience: Jena Bioscience manufactures modified nucleotides and cap analogs for mRNA research and therapeutic applications, including trinucleotide cap analogs similar to ExploRNA's AvantCap. They are a direct competitor in the European research reagent market.
• OZ Biosciences: OZ Biosciences is both a partner (distributing ExploCap-capped mRNA) and a competitor in mRNA transfection reagents and LNP delivery. They offer capped mRNA products globally, overlapping with ExploRNA's custom mRNA synthesis service.

Broad incumbents

• New England Biolabs: New England Biolabs is a major life sciences reagent manufacturer producing cap analogs, mRNA capping enzymes, and IVT reagents. They compete in the same customer workflow as ExploRNA, with a much broader product portfolio and established global distribution.
• Thermo Fisher Scientific (mRNA services): Thermo Fisher provides end-to-end mRNA manufacturing services including cap analog supply, custom mRNA synthesis, and LNP formulation through its Patheon and Biosciences divisions, serving the same pharmaceutical customers as ExploRNA but at much greater scale.
• BioNTech: BioNTech manufactures cap analogs internally for its COVID-19 vaccine and oncology pipeline, and is also developing mRNA therapeutics. While not directly selling cap analogs externally, they represent both the largest potential customer base and the primary competitive threat if they advance proprietary capping chemistry.
• Moderna: Moderna develops mRNA therapeutics and vaccines with internal cap analog chemistry capabilities. Similar to BioNTech, they represent both the largest addressable customer segment and a competitive threat through in-house R&D on capping technology.
• Curia (formerly AMRI): Curia is a contract development and manufacturing organization (CDMO) offering mRNA manufacturing services including proprietary capping chemistry. They compete with ExploRNA's custom mRNA and contract manufacturing value proposition at larger scale.

Regional players

• Hongene Biotech: Hongene Biotech is a major China-based manufacturer of nucleotides, modified nucleosides, and mRNA-related raw materials including cap analogs. They primarily serve Asian markets but compete globally in cap analog supply for mRNA manufacturing.

Emerging players

• GenScript: GenScript provides custom mRNA synthesis and gene synthesis services with growing cap analog offerings. They overlap with ExploRNA's e-commerce-based custom mRNA service, particularly for academic and biotech customers in Asia and globally.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/explorna-therapeutics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ExploRNA Therapeutics